Press releases

Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

Sanofi Q3 well on track

Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation

Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis

Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

Sanofi : Availability of the Pre-quarterly Results Communication

Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed